DUPIXENT is a targeted therapy towards IL-4 and IL-13 signalling, key drivers of persistent underlying Type 2 inflammation1,6
DUPIXENT (dupilumab) is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years or older and for severe AD in children aged 6–11 years, who are candidates for systemic therapy1
>300,000
patients2
aged ≥ 12 years with moderate-to-severe AD and children 6–11 years with severe AD, have been prescribed DUPIXENT worldwide as of July 20212
Real-world experience (RWE) has outcome data similar to that from Phase 3 clinical trials3–5
Learn about the different reimbursement criteria for DUPIXENT for people ≥ 12 years with moderate-to-severe AD and children 6–11 years with severe AD
LATEST NEWS & EVENTS
Efficacy in children
Explore the efficacy data in children aged 6-11 years old with severe AD
Safety profile in children
Learn more about the safety profile of DUPIXENT in children aged 6–11 years old with severe AD
Find out more about how DUPIXENT has been investigated in adult and adolescent patients with moderate-to-severe AD and children (6–11) with severe AD.
- DUPIXENT Summary of Product Characteristics. September 2021.
- Sanofi Data on File. MAT-IE-2000837 (v3.0).
- Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
- Sears AV, et al. Br J Dermatol. 2020. doi: 10.1111/bjd.19631. Online ahead of print.
- Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Poster P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
- Gandhi NA, et al. Nature Rev Drug Disc. 2016; 15: 35–50.
AD, atopic dermatitis; IL, interleukin.
References
MAT-IE-2101039(v4.0) | Date of preparation: February 2022
